Back to Search
Start Over
Cyclin D1 expression in penile cancer.
- Source :
-
Oncotarget [Oncotarget] 2024 May 14; Vol. 15, pp. 302-311. Date of Electronic Publication: 2024 May 14. - Publication Year :
- 2024
-
Abstract
- The main goal of the present study was to analyze the expression profile of cyclin D1 in patients with PC, and to determine possible correlations with clinical and histopathological features. A survey was conducted with 100 patients diagnosed with PC, who were treated at two reference hospitals in São Luís, Maranhão, Brazil, between 2013 and 2017. A review of clinical, epidemiological, and histopathological data was performed, Human Papillomavírus (HPV) DNA was detected using polymerase chain reaction (PCR) and cyclin D1 expression analysis was performed using immunohistochemical techniques. The data revealed that the absence of cyclin D1 expression was significantly associated with HPV-positive histological subtypes ( p = 0.001), while its expression was associated with high-grade tumors ( p = 0.014), histological subtype ( p = 0.001), presence of sarcomatoid transformation ( p = 0.04), and perineural invasion ( p = 0.023). Patients with cyclin D1 expression exhibited lower disease-free survival compared to the cyclin D1-negative group, although the difference was not statistically significant. The results suggest that cyclin D1 may be a potential biomarker for PC, especially for poorer prognosis.
- Subjects :
- Adult
Aged
Aged, 80 and over
Humans
Male
Middle Aged
Brazil epidemiology
Disease-Free Survival
Immunohistochemistry
Papillomavirus Infections virology
Papillomavirus Infections metabolism
Prognosis
Biomarkers, Tumor metabolism
Biomarkers, Tumor genetics
Cyclin D1 metabolism
Cyclin D1 genetics
Penile Neoplasms genetics
Penile Neoplasms pathology
Penile Neoplasms virology
Subjects
Details
- Language :
- English
- ISSN :
- 1949-2553
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Oncotarget
- Publication Type :
- Academic Journal
- Accession number :
- 38742684
- Full Text :
- https://doi.org/10.18632/oncotarget.28584